Shrinking sample sizes in lung cancer trials: Various explanations, open questions
In patients with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable mutation, checkpoint inhibitor therapies (CPI), have become the backbone of the first-line therapy [1]. However, many patients don ’t benefit from it, with their prognosis remaining rather poor once reached second line. During 2023, three randomized clinical trials (RCT) in this setting were reported, in which the sample size was reduced during accrual. Here we discuss the reasons for those decisions and their potential impli cations in interpreting trials’ results.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Timoth ée Olivier, Alfredo Addeo Tags: Letter to the Editor Source Type: research